On this page
Aicardi-Goutières syndrome
AGS is a complex genetic condition that typically presents in early infancy or childhood, impacting neurological development and function. It often leads to severe disability due to inflammation within the brain and other body systems.
Available at Jeen Health
Clinical tests that include this
Overview
Aicardi-Goutières syndrome (AGS) is a rare, inherited disorder that mainly affects the brain and immune system. It typically begins in early infancy, though in some cases, symptoms may appear later in childhood or even before birth. AGS can lead to significant neurological problems, including developmental delays, movement difficulties, and specific brain abnormalities visible on imaging scans.
The condition involves an overactive immune response, which can cause inflammation, particularly in the brain. This inflammation can mimic viral infections, even in the absence of a detectable virus, leading to progressive damage. AGS is classified as a leucodystrophy, a group of disorders that affect the white matter of the brain, although it has distinct features.
Symptoms & clinical features
The symptoms of Aicardi-Goutières syndrome can vary, but typically manifest in the first year of life. Common signs often include a period of normal development followed by a rapid onset of symptoms, such as irritability, feeding difficulties, and a slowing of head growth. Some infants may be born with symptoms including an enlarged liver and spleen, or skin lesions. In cases with later onset, symptoms might develop more gradually [PMID:33678082].
Neurological symptoms are prominent and can include spasticity (muscle stiffness) in the limbs, dystonia (involuntary muscle contractions), and seizures. Developmental regression, where a child loses previously acquired skills, is also characteristic. Other features can include chilblain-like skin lesions, glaucoma (increased pressure in the eye), and a persistent fever without infection. The severity of these symptoms can differ significantly between individuals.
Video: Genetics 101
Affected organs
AGS primarily affects the central nervous system, particularly the brain and spinal cord. The white matter of the brain, which helps transmit signals, is often damaged due to chronic inflammation. This can lead to calcifications (calcium deposits) in specific brain regions, visible on imaging.
Beyond the brain, AGS can also affect other body systems. The immune system is directly involved in the disease process, typically showing signs of chronic innate immune activation. The skin can be affected, with lesions resembling chilblains, particularly on fingers and toes. The liver and spleen may also be enlarged in some individuals at birth or shortly thereafter. Eye problems, such as glaucoma, have also been reported in some cases [PMID:28795777].
Risks & severity
Aicardi-Goutières syndrome typically presents with severe neurological impairment. The onset of symptoms is usually in infancy, often leading to a period of rapid decline in neurological function. Most affected children experience profound global developmental delay and significant physical disability. The condition is often progressive, meaning symptoms tend to worsen over time, though the rate of progression can vary.
While the condition is severe, the exact course and life expectancy can differ based on the specific gene involved and the severity of symptoms. Some individuals may have a milder presentation with later onset and slower progression, but this is less common. Early diagnosis and symptomatic management are important to improve quality of life.
Genetic causes
Aicardi-Goutières syndrome is caused by pathogenic variants (sometimes called mutations) in several different genes. These genes include ADAR, IFIH1, RNASEH2A, SAMHD1, and TREX1. Each of these genes plays a crucial role in managing nucleic acids (DNA and RNA) within cells or in immune regulation.
For example, TREX1 codes for an enzyme that helps break down DNA, preventing its accumulation in the cell where it could trigger an unwanted immune response [PMID:23789399]. Similarly, RNASEH2A is part of a complex that processes RNA-DNA hybrid molecules. Pathogenic variants in these genes disrupt these processes, leading to an abnormal build-up of nucleic acids. This accumulation incorrectly signals the immune system, leading to chronic inflammation that damages the brain and other tissues, characteristic of AGS.
- ADAR adenosine deaminase RNA specific
- IFIH1 interferon induced with helicase C domain 1
- RNASEH2A ribonuclease H2 subunit AThe RNASEH2A gene provides instructions for a component of the RNase H2 complex, an enzyme crucial for processing RNA-DNA hybrids and maintaining genomic stability.
- SAMHD1 SAM and HD domain containing deoxynucleoside triphosphate triphosphohydrolase 1The SAMHD1 gene provides instructions for an enzyme crucial in regulating cellular deoxynucleoside triphosphate (dNTP) levels, essential for DNA replication, repair, and immune responses against viruses.
- TREX1 three prime repair exonuclease 1
Inheritance pattern
Aicardi-Goutières syndrome is inherited in an autosomal recessive pattern. This means that an individual must inherit two pathogenic variants - one from each parent - to develop the condition. Typically, the parents are carriers, meaning they each have one pathogenic variant but do not show symptoms of the disorder themselves.
When both parents are carriers, there is a 1 in 4 (25%) chance with each pregnancy that their child will inherit two pathogenic variants and be affected by AGS. There is a 2 in 4 (50%) chance that their child will be a carrier like them, and a 1 in 4 (25%) chance that their child will inherit two unaffected copies of the gene and will neither have the condition nor be a carrier. Family members of an affected individual may be offered genetic counselling to discuss carrier testing and reproductive options.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosing Aicardi-Goutières syndrome often begins with clinical assessment based on the characteristic neurological and immunological features, particularly in infancy. Brain imaging, such as an MRI or CT scan, often reveals calcifications in the brain and white matter changes, which are key indicators. Lumbar puncture to analyse cerebrospinal fluid (CSF) may show elevated white blood cell counts and increased interferon-alpha levels, common in AGS.
Confirmation of AGS relies on genetic testing. A clinical geneticist or neurologist would typically refer individuals for testing, often through the NHS Genomic Medicine Service. The relevant NHS National Genomic Test Directory R-codes for suspected AGS would guide this process, allowing for targeted sequencing of the known causative genes (e.g., ADAR, IFIH1, RNASEH2A, SAMHD1, TREX1). Positive results identifying pathogenic variants in two copies of one of these genes confirm the diagnosis.
Management & lifestyle
Management for Aicardi-Goutières syndrome is primarily supportive, aiming to alleviate symptoms and improve the individual's quality of life. There is currently no cure for AGS, but multidisciplinary care is crucial. This typically involves paediatricians, neurologists, physiotherapists, occupational therapists, and speech and language therapists.
Treatment strategies may include medications to manage seizures, muscle stiffness (spasticity), and dystonia. Nutritional support may also be necessary for feeding difficulties. While some trials exploring immunomodulatory therapies are underway, there isn't a universally established treatment to stop the disease progression. Regular monitoring for complications such as glaucoma or other systemic issues is also part of comprehensive care. Families are encouraged to engage with genetic counsellors and patient support groups for guidance and resources.
UK care pathway
In the UK, individuals suspected of having Aicardi-Goutières syndrome are typically referred to specialist paediatric neurology services or clinical genetics departments. Genetic testing, guided by the NHS National Genomic Test Directory R-codes, is integral for confirming a diagnosis. Genetic counsellors play a vital role in explaining the inheritance pattern, discussing the implications of a diagnosis, and supporting families through testing and beyond, helping them navigate the complex care pathway within the NHS.
Frequently asked questions
What is the life expectancy for someone with Aicardi-Goutières syndrome?
Life expectancy for individuals with AGS varies significantly depending on the severity of the condition and the specific genetic cause. Many children with severe forms may not survive beyond early childhood, but individuals with milder forms can live into adolescence or adulthood. Supportive care aims to improve quality of life throughout their lives.
Is Aicardi-Goutières syndrome always inherited from parents?
Yes, Aicardi-Goutières syndrome is an inherited genetic condition. It follows an autosomal recessive pattern, meaning both parents must be carriers of a pathogenic variant in the same gene for their child to be affected. Less commonly, new pathogenic variants can arise in an individual, but this is rare.
Can Aicardi-Goutières syndrome be detected during pregnancy?
In some cases where there is a known family history and the specific genetic cause has been identified, prenatal diagnosis through chorionic villus sampling or amniocentesis may be possible. This would involve testing for the specific pathogenic variants in the foetus. Ultrasound may show features suggestive of AGS, but does not provide a definitive diagnosis.
Are there different types of Aicardi-Goutières syndrome?
While it's considered a single syndrome, AGS is genetically heterogeneous, meaning it can be caused by pathogenic variants in several different genes (e.g., ADAR, IFIH1, RNASEH2A, SAMHD1, TREX1). The specific gene involved can sometimes influence the severity and certain features of the condition, though there is significant overlap in symptoms across the different genetic causes.
What support is available for families affected by AGS in the UK?
Families in the UK can access support through specialist NHS services, including clinical genetics teams, paediatric neurologists, and genetic counsellors. There are also charities and patient support groups dedicated to rare neurological conditions and AGS specifically, which offer valuable resources, information, and peer support.
References
- Liu A, Ying S. Aicardi-Goutières syndrome: A monogenic type I interferonopathy. Scandinavian journal of immunology. 2023. PMID: 37515439
- Thakkar RN, Patel D, Kioutchoukova IP. Leukodystrophy Imaging: Insights for Diagnostic Dilemmas. Medical sciences (Basel, Switzerland). 2024. PMID: 38390857
- Mendonça LO, Frémond ML. Interferonopathies: From concept to clinical practice. Best practice & research. Clinical rheumatology. 2024. PMID: 39122631
- Hofer MJ, Modesti N, Coufal NG. The prototypical interferonopathy: Aicardi-Goutières syndrome from bedside to bench. Immunological reviews. 2024. PMID: 39473130
- Rice G, Patrick T, Parmar R. Clinical and molecular phenotype of Aicardi-Goutieres syndrome. American journal of human genetics. 2007. PMID: 17846997
- Adam MP, Bick S, Mirzaa GM. Aicardi-Goutières Syndrome. 1993. PMID: 20301648
- Dai J, Huang YJ, He X. Acetylation Blocks cGAS Activity and Inhibits Self-DNA-Induced Autoimmunity. Cell. 2019. PMID: 30799039
- Chung H, Calis JJA, Wu X. Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown. Cell. 2018. PMID: 29395325